65,437 trials
Adolescent Well-Being · Mental Disorders, Severe
Primary: Average Z-score From Participant Self Report on Domains in the Clinical Scale of the Treatment Outcome Package (TOP-CS) at Study Intervention Endpoint — 0.42; 0.63 Z-score
Hereditary Angioedema (HAE)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 5; 11 Participants
Chronic Pain
Primary: Change in Pain Interference — 4.91; 5.49; 5.69 scores on a scale — p=.02
Hereditary Angioedema
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 146 Participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Uveal Melanoma With Liver Metastases
Primary: Objective Response Rate (ORR) — 3 Participants
Peripheral Artery Disease
Primary: 4-month Change in Six-minute Walk Distance — -17.13; 23.06 meters — p=0.9640
Paroxysmal Nocturnal Hemoglobinuria
Primary: Percentage Change From Baseline in LDH at Week 12 — -76.5 percentage change — p=<0.001
Obesity · Diabetes Mellitus, Type 2
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 4 Participants
Recurrent Head and Neck Cancer · Head and Neck Cancer · Head and Neck Neoplasms
Primary: Objective Response Rate — 13 Participants
Diabetes Mellitus, Type 1
Primary: Overall Percent Time Less Than 54 mg/dL — 0.1; 0.1; 0.2; 0.2 percentage of time
Eosinophilic Esophagitis
Primary: Ratio of AUC0-Inf for AQ280 Capsule vs Oral Suspension — 0.976 Ratio of AUC0-Inf for AQ280 Cap vs Tab
Diabetes
Primary: Plantar Pressure - Standard of Care — 202.71 kPa
Post Traumatic Stress Disorder
Primary: Change in Amygdala Reactivity During Fear Processing Pre- to Post-treatment — 0.219; 0.188; 0.166; 0.138 BOLD signal
Food Selection · Nutrition · Food Preferences
Primary: Healthfulness of Product Selection — 64; 60.1; 62.6; 57.9 score on a scale